Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9555
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Armandi, A. | - |
dc.contributor.author | Sanavia, T. | - |
dc.contributor.author | Younes, R. | - |
dc.contributor.author | Caviglia, G. P. | - |
dc.contributor.author | Rosso, C. | - |
dc.contributor.author | Govaere, O. | - |
dc.contributor.author | Liguori, A. | - |
dc.contributor.author | Francione, P. | - |
dc.contributor.author | Gallego-Duran, R. | - |
dc.contributor.author | Ampuero, J. | - |
dc.contributor.author | Pennisi, G. | - |
dc.contributor.author | Aller, R. | - |
dc.contributor.author | Tiniakos, D. | - |
dc.contributor.author | Burt, A. | - |
dc.contributor.author | David, E. | - |
dc.contributor.author | Vecchio, F. | - |
dc.contributor.author | Maggioni, M. | - |
dc.contributor.author | Cabibi, D. | - |
dc.contributor.author | McLeod, Duncan | - |
dc.contributor.author | Pareja, M. J. | - |
dc.contributor.author | Zaki, M. Y. W. | - |
dc.contributor.author | Grieco, A. | - |
dc.contributor.author | Stal, P. | - |
dc.contributor.author | Kechagias, S. | - |
dc.contributor.author | Fracanzani, A. L. | - |
dc.contributor.author | Valenti, L. | - |
dc.contributor.author | Miele, L. | - |
dc.contributor.author | Fariselli, P. | - |
dc.contributor.author | Eslam, Mohammed | - |
dc.contributor.author | Petta, S. | - |
dc.contributor.author | Hagstrom, H. | - |
dc.contributor.author | George, Jacob | - |
dc.contributor.author | Schattenberg, J. M. | - |
dc.contributor.author | Romero-Gomez, M. | - |
dc.contributor.author | Anstee, Q. M. | - |
dc.contributor.author | Bugianesi, E. | - |
dc.date.accessioned | 2024-05-16T03:11:04Z | - |
dc.date.available | 2024-05-16T03:11:04Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Gut 73(5):825-834, 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9555 | - |
dc.description.abstract | OBJECTIVE: Hyperferritinaemia is associated with liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed the role of serum ferritin in predicting long-term outcomes or death. DESIGN: We evaluated the relationship between baseline serum ferritin and longitudinal events in a multicentre cohort of 1342 patients. Four survival models considering ferritin with confounders or non-invasive scoring systems were applied with repeated five-fold cross-validation schema. Prediction performance was evaluated in terms of Harrell's C-index and its improvement by including ferritin as a covariate. RESULTS: Median follow-up time was 96 months. Liver-related events occurred in 7.7%, hepatocellular carcinoma in 1.9%, cardiovascular events in 10.9%, extrahepatic cancers in 8.3% and all-cause mortality in 5.8%. Hyperferritinaemia was associated with a 50% increased risk of liver-related events and 27% of all-cause mortality. A stepwise increase in baseline ferritin thresholds was associated with a statistical increase in C-index, ranging between 0.02 (lasso-penalised Cox regression) and 0.03 (ridge-penalised Cox regression); the risk of developing liver-related events mainly increased from threshold 215.5 microg/L (median HR=1.71 and C-index=0.71) and the risk of overall mortality from threshold 272 microg/L (median HR=1.49 and C-index=0.70). The inclusion of serum ferritin thresholds (215.5 microg/L and 272 microg/L) in predictive models increased the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score in the longitudinal risk assessment of liver-related events (C-indices>0.71) and overall mortality (C-indices>0.65). CONCLUSIONS: This study supports the potential use of serum ferritin values for predicting the long-term prognosis of patients with MASLD. Copyright Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. | - |
dc.subject | Non-alcoholic Fatty Liver Disease | - |
dc.subject | Liver Cirrhosis | - |
dc.subject | Fibrosis | - |
dc.subject | Liver Neoplasms | - |
dc.subject | Ferritins | - |
dc.title | Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1136/gutjnl-2023-330815 | - |
dc.subject.keywords | Gastroenterology and Hepatology | - |
dc.identifier.journaltitle | Gut | - |
dc.identifier.department | Storr Liver Centre | - |
dc.contributor.wslhd | McLeod, Duncan | - |
dc.contributor.wslhd | Eslam, Mohammed | - |
dc.contributor.wslhd | George, Jacob | - |
dc.identifier.pmid | 38199805 | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.